These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12455303)

  • 41. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.
    Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Cervek J; Fowst C; Polli A; Di Salle E; Massimini G; Piscitelli G
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S86-7. PubMed ID: 11056333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exemestane metabolites suppress growth of estrogen receptor-positive breast cancer cells by inducing apoptosis and autophagy: A comparative study with Exemestane.
    Amaral C; Lopes A; Varela CL; da Silva ET; Roleira FM; Correia-da-Silva G; Teixeira N
    Int J Biochem Cell Biol; 2015 Dec; 69():183-95. PubMed ID: 26515125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The evolving role of aromatase inhibitors in breast cancer.
    Mokbel K
    Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
    Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB
    Am J Health Syst Pharm; 2005 Feb; 62(3):266-73. PubMed ID: 15719584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
    Chen D; Hackl W; Ortmann O; Treeck O
    Anticancer Drugs; 2004 Jan; 15(1):55-61. PubMed ID: 15090744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
    Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
    J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
    Campos SM; Guastalla JP; Subar M; Abreu P; Winer EP; Cameron DA
    Clin Breast Cancer; 2009 Feb; 9(1):39-44. PubMed ID: 19299239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
    Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
    Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Dodwell D; Vergote I
    Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intergroup Exemestane Study mature analysis: overall survival data.
    Jassem J;
    Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
    Lønning PE
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aromatase inhibitors: new endocrine treatment of breast cancer.
    Brueggemeier RW
    Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
    Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.